Management of Subtherapeutic INR on Warfarin

Immediate Assessment

For a patient with INR 1.4 on warfarin, the American College of Cardiology recommends increasing the weekly warfarin dose by 5-20% and rechecking the INR within 3-7 days, as this subtherapeutic level provides inadequate anticoagulation and requires dose adjustment without any need for vitamin K administration 1
Verify the indication for anticoagulation and confirm the target INR range, typically 2.0-3.0 for most indications, including atrial fibrillation, venous thromboembolism, and bileaflet mechanical aortic valves; 2.5-3.5 for mechanical mitral valves or older valve types 1
Assess thromboembolic risk during this period of subtherapeutic anticoagulation, particularly in high-risk patients such as those with mechanical mitral valves, recent thromboembolism, or history of stroke 2, 3

Identify causes of the low INR, including increased dietary vitamin K intake, which can affect warfarin metabolism 1

Consider bridging anticoagulation with low molecular weight heparin (LMWH) only in very high-risk patients, such as those with mechanical mitral valve, recent thromboembolism within 3 months, or history of thromboembolism while anticoagulated 2, 3
Screen for medication interactions, including over-the-counter drugs, antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and herbal supplements that may be affecting warfarin metabolism 1
Assess dietary vitamin K intake consistency, as fluctuations in vitamin K consumption are a common cause of INR instability 1

Do not give vitamin K for subtherapeutic INR, as vitamin K is only indicated for elevated INR values with or without bleeding, according to the American College of Cardiology 1, 4

The American College of Chest Physicians recommends against routinely administering bridging therapy for a single subtherapeutic INR in stable patients (Grade 2C) 5

For the vast majority of patients with atrial fibrillation or remote VTE history, bridging is not indicated for a single low INR, as recommended by the American College of Chest Physicians 5

Once INR returns to therapeutic range (2.0-3.0), continue monitoring at standard intervals, as suggested by the American College of Chest Physicians 6

The American College of Chest Physicians found no significant difference in thromboembolic events between bridged and non-bridged patients with single subtherapeutic INR values (Grade 2C recommendation) 5